vs
ARDELYX, INC.（ARDX）与Ecovyst Inc.（ECVT）财务数据对比。点击上方公司名可切换其他公司
Ecovyst Inc.的季度营收约是ARDELYX, INC.的2.1倍（$199.4M vs $94.5M），Ecovyst Inc.同比增速更快（34.0% vs 27.5%），过去两年Ecovyst Inc.的营收复合增速更高（18.7% vs 13.6%）
Ardelyx是一家商业化阶段的生物制药企业，专注于研发和商业化针对胃肠道、心肾及代谢类疾病的创新疗法，其核心产品已在美国获批用于治疗便秘型肠易激综合征，同时拥有涵盖多适应症的各阶段研发管线。
Ecovyst Inc.是一家全球可持续特种材料供应商，主营高性能催化剂与功能性添加剂的研发、生产，产品服务覆盖工业制造、消费品、环保等核心领域，助力全球客户提升运营效率、降低碳排放。
ARDX vs ECVT — 直观对比
营收规模更大
ECVT
是对方的2.1倍
$94.5M
营收增速更快
ECVT
高出6.5%
27.5%
两年增速更快
ECVT
近两年复合增速
13.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $94.5M | $199.4M |
| 净利润 | $-37.6M | — |
| 毛利率 | — | 23.4% |
| 营业利润率 | — | 10.9% |
| 净利率 | -39.8% | — |
| 营收同比 | 27.5% | 34.0% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-0.15 | $0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARDXECVT
| Q1 26 | $94.5M | — | ||
| Q4 25 | $125.2M | $199.4M | ||
| Q3 25 | $110.3M | $204.9M | ||
| Q2 25 | $97.7M | $176.1M | ||
| Q1 25 | $74.1M | $143.1M | ||
| Q4 24 | $116.1M | $148.9M | ||
| Q3 24 | $98.2M | $153.9M | ||
| Q2 24 | $73.2M | $154.0M |
净利润ARDXECVT
| Q1 26 | $-37.6M | — | ||
| Q4 25 | $-407.0K | — | ||
| Q3 25 | $-969.0K | $-79.3M | ||
| Q2 25 | $-19.1M | $6.0M | ||
| Q1 25 | $-41.1M | $-3.6M | ||
| Q4 24 | $4.6M | — | ||
| Q3 24 | $-809.0K | $14.3M | ||
| Q2 24 | $-16.5M | $8.3M |
毛利率ARDXECVT
| Q1 26 | — | — | ||
| Q4 25 | 91.3% | 23.4% | ||
| Q3 25 | 96.4% | 25.4% | ||
| Q2 25 | 87.3% | 22.8% | ||
| Q1 25 | 83.4% | 13.3% | ||
| Q4 24 | 84.3% | 28.9% | ||
| Q3 24 | 84.0% | 29.3% | ||
| Q2 24 | 87.1% | 27.3% |
营业利润率ARDXECVT
| Q1 26 | — | — | ||
| Q4 25 | 4.1% | 10.9% | ||
| Q3 25 | 4.2% | 13.8% | ||
| Q2 25 | -14.7% | 9.0% | ||
| Q1 25 | -49.0% | -0.7% | ||
| Q4 24 | 7.0% | 15.1% | ||
| Q3 24 | 2.3% | 17.9% | ||
| Q2 24 | -18.6% | 14.1% |
净利率ARDXECVT
| Q1 26 | -39.8% | — | ||
| Q4 25 | -0.3% | — | ||
| Q3 25 | -0.9% | -38.7% | ||
| Q2 25 | -19.5% | 3.4% | ||
| Q1 25 | -55.5% | -2.5% | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | -0.8% | 9.3% | ||
| Q2 24 | -22.5% | 5.4% |
每股收益（稀释后）ARDXECVT
| Q1 26 | $-0.15 | — | ||
| Q4 25 | $-0.01 | $0.06 | ||
| Q3 25 | $0.00 | $-0.69 | ||
| Q2 25 | $-0.08 | $0.05 | ||
| Q1 25 | $-0.17 | $-0.03 | ||
| Q4 24 | $0.01 | $-0.26 | ||
| Q3 24 | $0.00 | $0.12 | ||
| Q2 24 | $-0.07 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $238.1M | $197.2M |
| 总债务越低越好 | $203.5M | $392.6M |
| 股东权益账面价值 | $148.6M | $603.4M |
| 总资产 | $504.5M | $1.3B |
| 负债/权益比越低杠杆越低 | 1.37× | 0.65× |
8季度趋势，按日历期对齐
现金及短期投资ARDXECVT
| Q1 26 | $238.1M | — | ||
| Q4 25 | $68.0M | $197.2M | ||
| Q3 25 | $42.7M | $82.0M | ||
| Q2 25 | $90.0M | $69.6M | ||
| Q1 25 | $30.8M | $127.5M | ||
| Q4 24 | $64.9M | $131.4M | ||
| Q3 24 | $47.4M | $123.5M | ||
| Q2 24 | $41.9M | $83.3M |
总债务ARDXECVT
| Q1 26 | $203.5M | — | ||
| Q4 25 | $202.8M | $392.6M | ||
| Q3 25 | $202.1M | $854.8M | ||
| Q2 25 | $201.4M | $856.6M | ||
| Q1 25 | $151.3M | $859.0M | ||
| Q4 24 | $150.9M | $860.8M | ||
| Q3 24 | $100.7M | $862.7M | ||
| Q2 24 | $100.2M | $862.4M |
股东权益ARDXECVT
| Q1 26 | $148.6M | — | ||
| Q4 25 | $166.9M | $603.4M | ||
| Q3 25 | $154.3M | $607.9M | ||
| Q2 25 | $139.5M | $692.4M | ||
| Q1 25 | $145.7M | $698.7M | ||
| Q4 24 | $173.3M | $700.5M | ||
| Q3 24 | $158.3M | $729.4M | ||
| Q2 24 | $147.0M | $717.3M |
总资产ARDXECVT
| Q1 26 | $504.5M | — | ||
| Q4 25 | $501.6M | $1.3B | ||
| Q3 25 | $486.2M | $1.7B | ||
| Q2 25 | $466.8M | $1.8B | ||
| Q1 25 | $410.2M | $1.8B | ||
| Q4 24 | $435.8M | $1.8B | ||
| Q3 24 | $367.9M | $1.8B | ||
| Q2 24 | $343.5M | $1.8B |
负债/权益比ARDXECVT
| Q1 26 | 1.37× | — | ||
| Q4 25 | 1.21× | 0.65× | ||
| Q3 25 | 1.31× | 1.41× | ||
| Q2 25 | 1.44× | 1.24× | ||
| Q1 25 | 1.04× | 1.23× | ||
| Q4 24 | 0.87× | 1.23× | ||
| Q3 24 | 0.64× | 1.18× | ||
| Q2 24 | 0.68× | 1.20× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $41.8M |
| 自由现金流经营现金流 - 资本支出 | — | $22.9M |
| 自由现金流率自由现金流/营收 | — | 11.5% |
| 资本支出强度资本支出/营收 | — | 9.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $69.9M |
8季度趋势，按日历期对齐
经营现金流ARDXECVT
| Q1 26 | — | — | ||
| Q4 25 | $21.0M | $41.8M | ||
| Q3 25 | $365.0K | $55.3M | ||
| Q2 25 | $-25.3M | $33.0M | ||
| Q1 25 | $-38.5M | $10.3M | ||
| Q4 24 | $9.8M | $43.5M | ||
| Q3 24 | $501.0K | $59.9M | ||
| Q2 24 | $-19.4M | $10.0M |
自由现金流ARDXECVT
| Q1 26 | — | — | ||
| Q4 25 | $20.6M | $22.9M | ||
| Q3 25 | $209.0K | $53.2M | ||
| Q2 25 | $-26.0M | $7.8M | ||
| Q1 25 | $-38.8M | $-14.0M | ||
| Q4 24 | $9.2M | $30.9M | ||
| Q3 24 | $364.0K | $53.6M | ||
| Q2 24 | $-19.5M | $-9.3M |
自由现金流率ARDXECVT
| Q1 26 | — | — | ||
| Q4 25 | 16.4% | 11.5% | ||
| Q3 25 | 0.2% | 26.0% | ||
| Q2 25 | -26.6% | 4.4% | ||
| Q1 25 | -52.3% | -9.8% | ||
| Q4 24 | 7.9% | 20.7% | ||
| Q3 24 | 0.4% | 34.9% | ||
| Q2 24 | -26.7% | -6.1% |
资本支出强度ARDXECVT
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 9.4% | ||
| Q3 25 | 0.1% | 1.0% | ||
| Q2 25 | 0.7% | 14.4% | ||
| Q1 25 | 0.4% | 16.9% | ||
| Q4 24 | 0.5% | 8.5% | ||
| Q3 24 | 0.1% | 4.1% | ||
| Q2 24 | 0.2% | 12.5% |
现金转化率ARDXECVT
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 5.52× | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.11× | — | ||
| Q3 24 | — | 4.21× | ||
| Q2 24 | — | 1.20× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARDX
| IBSRELA | $70.1M | 74% |
| XPHOZAH | $23.3M | 25% |
| Non-cash royalty revenue related to the sale of future royalties | $695.0K | 1% |
| Product supply revenue | $354.0K | 0% |
ECVT
| Industrial Mining Automotive | $101.3M | 51% |
| Regeneration And Treatment Services | $90.0M | 45% |
| Other | $8.1M | 4% |
